ProQR Therapeutics N.V. Annual Research And Development Expense in EUR from 2015 to 2023

Taxonomy & unit
ifrs-full: EUR
Summary
ProQR Therapeutics N.V. quarterly/annual Research And Development Expense history and growth rate from 2015 to 2023.
  • ProQR Therapeutics N.V. Research And Development Expense for the quarter ending September 30, 2024 was €9.41M, a 72.9% increase year-over-year.
  • ProQR Therapeutics N.V. Research And Development Expense for the twelve months ending September 30, 2024 was €33.5M, a 19.1% increase year-over-year.
  • ProQR Therapeutics N.V. annual Research And Development Expense for 2023 was €25.1M, a 50.6% decline from 2022.
  • ProQR Therapeutics N.V. annual Research And Development Expense for 2022 was €50.9M, a 20.5% increase from 2021.
  • ProQR Therapeutics N.V. annual Research And Development Expense for 2021 was €42.2M, a 10.7% increase from 2020.
Research And Development Expense, Trailing 12 Months (EUR)
Research And Development Expense, Annual (EUR)
Research And Development Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 25.1M -25.7M -50.6% Jan 1, 2023 Dec 31, 2023 20-F 2024-03-13
2022 50.9M +8.65M +20.5% Jan 1, 2022 Dec 31, 2022 20-F 2024-03-13
2021 42.2M +4.09M +10.7% Jan 1, 2021 Dec 31, 2021 20-F 2024-03-13
2020 38.1M -8.36M -18% Jan 1, 2020 Dec 31, 2020 20-F 2023-03-29
2019 46.5M +17M +57.5% Jan 1, 2019 Dec 31, 2019 20-F 2022-04-29
2018 29.5M -1.64M -5.26% Jan 1, 2018 Dec 31, 2018 20-F 2021-03-24
2017 31.2M -770K -2.41% Jan 1, 2017 Dec 31, 2017 20-F 2020-03-31
2016 31.9M +8.52M +36.4% Jan 1, 2016 Dec 31, 2016 20-F 2019-03-28
2015 23.4M Jan 1, 2015 Dec 31, 2015 20-F 2018-03-30
* An asterisk sign (*) next to the value indicates that the value is likely invalid.